Replay available

Ethos Technologies Inc. (LIFE) Q4 2022 Earnings Call

Ethos Technologies Inc. (NASDAQ: LIFE) Q4 2022 earnings conference call, held 2023-03-09. Replay captured from the company's public earnings webcast.

Thu, March 9, 2023 at 5:00 PMendedReplay
Ethos Technologies Inc. (LIFE) Q4 2022 Earnings Call

Hosted by

Featured presenters

Dr. Sanjay Shukla

President and CEO

Ashley Dunstan

Director of Investor Relations and Corporate Communications

Jill Broadfoot

Chief Financial Officer

Gregory Renza

Analyst, RBC Capital Markets

Joseph Pantagenas

Analyst, H.C. Wainwright & Co.

Yeo Jin

Analyst, Laidlaw & Company

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ethos Technologies Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.009 -- 00:00:03.431 Good afternoon, ladies and gentlemen, and welcome to the 8th Tower Farmer fourth quarter 00:00:03.431 -- 00:00:07.813 and full year 2022 conference call. At this time, all participants are on a listen-only 00:00:07.813 -- 00:00:11.375 mode. Later, we'll conduct a question and answer session, and instructions will be given 00:00:11.375 -- 00:00:16.518 at that time. As a reminder, this conference call is being recorded for replay purposes. 00:00:16.518 -- 00:00:20.200 It is now my pleasure to hand the conference over to Ashley Dunstan, 8th Tower's Director 00:00:20.200 -- 00:00:22.461 of Investor Relations and Corporate Communications. 00:00:22.461 -- 00:00:25.482 Ms. Dunstan, you may begin. 00:00:25.543 -- 00:00:30.428 Thank you, and good afternoon, everyone. Thank you for joining us today to discuss ATIRE's 00:00:30.428 -- 00:00:33.131 fourth quarter and full year 2022 00:00:33.131 -- 00:00:36.574 operating results and corporate update. We are joined today by Dr. 00:00:36.574 -- 00:00:39.337 Sanjay Shukla, our president and CEO, and Ms. 00:00:39.337 -- 00:00:44.262 Jill Broadfoot, our CFO. On the call, Sanjay will provide an update on our corporate 00:00:44.262 -- 00:00:49.639 strategy, including our clinical program for EpsoCitimod and research and discovery programs. 00:00:49.639 -- 00:00:54.021 Jill will review the financial results and our current financial position before handing 00:00:54.021 -- 00:00:56.963 it back to Sanjay to open the call for any questions. 00:00:56.963 -- 00:01:01.025 Before we begin, I would like to remind everyone that except for statements of historical 00:01:01.025 -- 00:01:05.027 facts, the statements made by management and responses to questions on this conference 00:01:05.027 -- 00:01:09.510 call a...